Kazia Therapeutics (KZIA) Non-Current Deffered Revenue (2016)
Kazia Therapeutics (KZIA) posted Non-Current Deffered Revenue of $613157.0 for Q4 2016, up 16.71% on a QoQ basis from $525379.1 in Q2 2016.
Kazia Therapeutics (KZIA) Non-Current Deffered Revenue (2016) Analysis & Trends
Kazia Therapeutics' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $613157.0 for Q4 2016.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $613157.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $613157.0 (changed N/A YoY) and the FY2016 annual result came in at $613157.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $613157.0 for Q4 2016 at Kazia Therapeutics, up from $525379.1 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $613157.0 in Q4 2016 and bottomed at $525379.1 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kazia Therapeutics | 4.11 Mn | 4.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 613,156.97 |
| Jun 30, 2016 | 525,379.07 |